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Summary
 
Background Epstein- Barr virus (EBV) is a ubiquitous in that infecting more than 90% of adult population 
worldwide. Recently, EBV has been linked to the development of variety of human malignancies including 
prostate tissues that range from benign prostatic hyperplasia (BPH) to prostatic adenocarcinoma (PAC). Somatic 
point mutations in Rb gene have been detected in prostate cancer and are involved in progression steps of 
prostate carcinogenesis. 
Objective: To analyze the distribution and impact of concordant Rb expression and latent EBV infection on a 
group of prostate adenocarcinoma and benign prostatic hyperplasia. 
Patients and methods: Seventy- two (72) formalin-fixed, paraffin- embedded  prostatic tissues were obtained in 
this study; (40) biopsies from prostatic carcinoma and  (20) from benign prostate hyperplasia as well as (12) 
apparently normal prostatic  autopsies control group. Detection of EBV-EBERs was done by ultra sensitive 
version of in situ hybridization method where as immunohistochemistry detection system was used to 
demonstrate the expression of Rb gene. 
Results:  Detection of EBV-EBERs -ISH reactions in tissues with PAC was observed in 19 out of 40 (47.5%), 
while in the tissues from BPH was detected in 10% (2 out of 20). No EBV-EBERs positive – ISH reaction was 
detected in healthy prostate tissues in the control group.   The differences between the percentages of EBERs 
detection in tissues PAC and each of BPH & control groups were statistically highly significant (P value = < 
0.0001).  
Positive Rb immunohistochemical (IHC) reactions were observed in 19 PAC cases (47.5%) and in 2 BPH cases 
(10%).   
Conclusions: Our results indicate that the EBV might contribute to the development of subset of prostate tumors. 
In addition, the significant percentage of expression of possible Rb gene as well as EBV in prostate 
adenocarcinoma could indicate for an important role of these molecular and viral factors in prostatic 
carcinogenesis. 
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Introduction  
Most common neoplasms of the male genital tract involve the prostate gland (1). Prostate cancer is the fifth 
common cancer world-wide and second in cancer mortality exceeded only by lung cancer (2, 3).   
Viral factors are the most important class of infectious agents associated with human cancers (4). It was 
estimated that 17-20% of all worldwide incidence of cancers are attributable to a viral etiology (5). 
EBV is a typical virus consisting of a core containing a linear, double stranded DNA; an icosahedral capsid, 
approximately 120-200 nm in  diameter, containing 162 capsomeres; an  amorphous material that surrounded the 
capsid,(tegument)and an envelope containing viral glycoprotein spikes on its surface(6). Sequence analysis has 
defined two strains of EBV : type I and type II ( alternatively named EBV A and B ) which differ at the domains 
that encode EBV latent proteins, namely EBERs, and the nuclear antigens EBNA-LP,1,2,3A,3B and 3C in 
latently infected cell(7). 
EBV has been classified as a group 1 carcinogen associated with a variety of lymphoid and epithelial 
malignancies by the international agency for research of cancer {IARC}(8). Evidence of EBV being a 
monogenic virus is drives from its ability to infect and transform normal human B cells in vitro, resulting in 
immortalization of these cells and leading to continuous growth of lymphoblastoid cell lines. Moreover, EBV 
can transform human squamous epithelial cells in vitro. The virus is involved in the development of several 
human cancers such as nasopharyngeal carcinoma and various lymphomas (9). 
The small untranslated RNAs (EBER-1 and-2) are accumulated at high levels during all forms of latency and 
regulate apoptosis through different mechanisms. EBER-1 interacts with the interferon-inducible protein kinase 
R (PKRO, and inhibits its activation by double-stranded RNAs, protecting infected cells from INF-induced 
apoptosis (10).  
EBV encoded small RNAs have however a more prominent role in EBV-mediated growth transformation, as 
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viruses lacking the coding sequence for this RNA were significantly less efficient in generating lymphoblastoid 
cell lines(LCLs) in vitro, and the cell lines generated proliferation at  much lower rates, due to reduced autocrine 
IL-6 production (11). These observations have been extended to epithelial cells lines, where EBERs induced the 
expression of growth factors that promote cell survival(12). 
The EBV latent proteins expression contribute to most, if not all, of the transforming  and immortalizing 
properties of this prototype DNA oncogenic viral agent. In addition to EBNA1 and the EBERs, human cancer 
cells , that are latently infected with this virus express the most powerful  oncogenic proteins, LMP-1 and LMP-
2(A and B) (10).    
Besides chromosomal loss and mutation , there are various other mechanisms for Rb inactivation. Also, Rb can 
be inactivated in tumors by the loss of one allele and hypermethylation of the other alleles(13). Interestingly, a 
recent survey of Rb status in metastatic breast cancer revealed two cases with duplication of the entire gene(14). 
This may be related to a phenomena observed in colorectal carcinoma, where high expression of  pRb was 
shown ,paradoxically ,to protect from E2F-induced  apoptosis (14,15).In addition ,expression of constitutively 
active phosph-mutant Rb transgenes in mouse mammary epithelium induces adenocarcinoma(16). Thus, both 
activation and inactivation of pRb can be oncogenic in the mammary gland (16). Rb inactivation was observed to 
increase the proliferative potential of the cells which was associated with over expression of cyclin dependent 
kinase (17). The deregulation of the Rb pathway is the primary function of each of the DNA tumor virus 
oncoproteins that promote cellular proliferation, this includes the adenovirus E1 A protein, polyoma  virus ,SV40 
T antigen and HPV E7 protein(18). Rb is functionally inactivated in 25-30% of prostate cancers; furthermore, Rb 
loss is correlated with increasing tumor stage and grade. The clinical consequences of Rb loss are unknown. It 
was shown previously that Rb loss results in a castrate resistant phenotype. The hypothesized that Rb loss would 
down regulate the G1-S cell cycle arrest normally induced by irradiation, inhibit DNA repair, and subsequently 
sensitize cells to mitotic catastrophe (19).   
Materials and methods: 
The study was designed as a retrospective one. It has recruited 72 selected formalin fixed, paraffin embedded 
prostatic tissue blocks among them; (40)  tissue biopsies  from  prostatic carcinoma  with different grades and 
(20) benign prostate hyperplastic tissue blocks  as well as (12) apparently normal prostate tissue  autopsies which  
were collected from the archives of Forensic Medicine Institute / Baghdad and used as  prostate healthy tissues 
control groups. The diagnosis of these tissue blocks were based on their accompanied records. A consultant 
pathologist reexamined all these cases to further confirm the diagnosis following trimming process of these 
tissue blocks. 
One section was mounted on ordinary glass slide and stained with hematoxyline and eosin, while another slide 
was mounted on charged slide to be used for ISH for detection of EBV .The detection of EBV-EBERs by ISH kit 
(Zyto Vision GmbH. Fischkai, Bremerhaven. Germany) was performed on 4µm paraffin embedded tissue 
sections using digoxigenin-labeled oligo-nucleotides probe which targets Epstein-Bar-Virus (EBV) EBER RNA. 
For the in situ hybridization procedure, the slides were placed in 60 C˚ hot-air oven over night then the tissue 
sections were de-paraffinized and via then incubation of slides for 15 min (twice time) in xylene  then treatment 
by graded alcohols via incubation for 5 min in 100% ethanol(twice time) .The same dewaxing were protocols 
routinely used for immunohistochemistry procedures, e.g. 15 min xylene (twice time), 5 min 100% ethanol(twice 
time), 5 min 96% ethanol(one time), 5 min 70% ethanol(one time), were  used, finally immersion in distilled 
water for 5 minutes to remove residual alcohol. After that, slides were allowed to dry completely by incubating 
them at 37°C for 5 minutes. Then we done digestion process by add proteinase K to the slides, then the slides 
were incubated at 37°C for 15 minutes. Then the slides were dehydrated by immersing them sequentially in the 
following solution at room temperature for the indicated times, distilled water for 1 minute, 70% ethanol for 1 
minute, 95% ethanol for 1 minute and 100% by incubating them at 37% for 5 minutes. Then we add the 20 µl of 
cDNA probe added to each section and slides were covered by cover slips be careful to avoid trapping any air 
bubbles. After that probe and target DNA  were  denaturated by placing the cover slipped-slides in pre-warmed 
oven at 95°C for 8-10 minutes, slides were transferred  to a pre-warmed humid hybridization chamber and 
incubated at 37°C for overnight. Then the slides were allowed not dry out at any time during the hybridization 
and staining. All reagents used during hybridization and detection were warmed to room temperature. At the 
next day, slides were soaked in pre-warmed protein block at 37°C until the cover slips fell off and should be 
careful not to tear the tissue, then the slides were allowed to remain in the buffer for 3 minutes, at 37°C after 
cover slips were removed. After that we add streptavidin-alkaline phosphatase conjugate reagent were added to 
tissue sections. Then slides were kept in a humid chamber at 37°C for 20 minutes. Then  one to two drops of 
Slides were rinsed in detergent wash buffer for 5 minutes and then drained. After that One to two drops of 5-
bromo3-chloro3-indoly/phosphate/nitro blue tertrazolium substrate-chromogen solution(BCIP/MBT) were 
placed on tissue section. Slides were incubated at 37 C˚ for 30 minutes or until color development was developed 
completed. Color development was monitored by viewing the slides under the microscope. A dark blue colored 
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precipitate form at the complementary site of the probe in positive cells. Then the slides  were rinsed in distilled  
water for 5 minutes, then counter staining process by immersion of the slides in Nuclear Fast Red  stain for 30 
seconds, then washing process was followed by immersion the slides for 1 minute in distilled water. After that 
Sections were dehydrated by ethyl alchol, (95%, once for one minute then, 100% twice times for 2 minutes each); 
cleared by Xylen, then mounted with permanent mounting medium (DPX). 
Immunohistochemistry / Detection system (US Biological Inc . USA) was used to demonstrate the Rb protein  
encoded by Rb tumor suppressor gene. This technique is based on the detection of the product of gene 
expression (protein ) in malignant and normal cells using a specific primary monoclonal mouse antihuman 
antibodies for specific epitope on that nuclear targeted protein . The bound primary antibody is then detected by 
secondary antibody (goat anti mouse ) , which contains specific label (used peroxidase labeled polymer 
conjugated to goat anti mouse immunoglobulin ) . The substrate is DAB in chromogen solution and the positive 
reaction has resulted in a brown color precipitate at the antigen site in tested tissues ( 20).  
Chi –square test was used to detect the significance of variables in our study. All the statistical analysis was done 
by SPSS program (Version– 17) & P value was considered significant when p <0.05. 
Results 
The distribution of Gleason’s grading of prostate carcinomaccording to the ISH results for EBV-EBERs 
detection. 
The EBV-EBERs positive results of 1SH were detected in 50% (8 out of 16) of tissues with prostatic cancers 
showing Gleason’s grade (8-10) (poorly differentiated grade), followed by the tissues showing  Gleason’s grade 
(5-7) (moderate differentiated grade) (i.e. 6 out of  13) where it comprised 46.2% of  the total number of this 
grade , and lastly by tissues with Gleason’s grade (2-4) (well differentiated grade) where it constituted 45.5% of 
total number of this grade (i.e. 5 out of 11). 
Statistically, the distribution of ISH results for detection of EBV-EBERs according to the Gleason’s grading of 
prostate carcinoma shows  non-significant  differences   (P>0,05) (table 1 ). 
Table (1): Distribution of ISH results for EBV-EBERs according to Gleason's grading of prostatic carcinoma   














Non*  Significant 
(P>0.05) 
% 45.5 54.5 100 
5-7 
 
N 6 7 13 
% 46.2 53.8 100 
8-10 N 8 8 16 
% 50 50 100 
Total N 19 21 40  
% 47.5 52.5 100 
*The difference in signal scoring  results for detection of EBV-EBERs-ISH according to the Gleason’s grading 
of prostate carcinoma shows  non-significant  differences   (P>0.05) [NS] (P Kruskal-Wallis = 0.15). 
The results of EBV- ISH among study groups 
It was found after application and analysis of (ISH) results of EBV--EBERs in the tissues obtained from patients 
with prostatic cancer as well as benign prostatic hyperplasia that (19) out of (40) patients with carcinoma of 
prostate showed positive in situ hybridization reaction where it constituted 47.5% of the total prostatic cancer 
cases of this study (table 2 and figure 1).  In the benign group, 10% has revealed positive signals, which 
represented 2 out of 20 cases in this group, whereas none of control group presented with positive signals for 
EBV-EBERs-ISH test.  However , in comparison to the percentage of EBV -EBERs in healthy control group as 
well as in the group of benign prostatic hyperplasia, the differences between the percentages of EBV-EBERs in 
prostatic cancers and each of these groups are statistically very highly significant (P value = < 0,001). 
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Table  (2):  Results of in situ hybridization for detecting EBV in tissues with prostatic tumors. 
 
 * The difference in signal scoring of positive reactions for EBV- EBERs  between benign prostatic hyperplasia 
and prostatic cancer groups (healthy controls are not part in this comparison, since all of them were negative) 



















Figure (1): In situ hybridization results for EBV-DNA detection in prostate tumors; BCIP/NBT stained and 
counter stained by nuclear fast red; A. Healthy Prostatic tissues  with negative ISH reaction for EBV (10X).B. 
prostate cancer with positive ISH reaction for EBV-DNA (40X). 
Co-existence of EBV-EBERs-ISH and Rb –IHC expression in tissues with prostatic cancers. 
The percentage of positive Rb-tumor suppressor gene expression that associated with positive EBV-EBERs  ISH 
reaction was constituted (63.2%:12 out of 19 cases) in prostatic cancer group, while the percentage of positive 
Rb expression was (36.8% :7 out of 19 cases) in prostatic cancerous tissues that showed EBV-EBERs-negative 
reaction by ISH technique. Also , in BPH the percentage of positive Rb-Tumor suppressor gene expression that 
showed also positive EBV- EBERS reaction was constituted (10%: 2 out of 20 cases) in prostatic cancer group, 
while the percentage of positive Rb expression in prostatic cancerous tissues that showed EBV-EBERS negative 
reaction was (28.6% : 4 out of 20 cases) (table 3 and figure 2). The statistical analysis showed significant 
association ( p<0.05) on comparing the results (according to score) when  group of prostate cancer  was 





EBV-EBERS -ISH Total Comparison of significance 
Positive Negative P-value Significance. 









% 47.5 52.5 100 
Benign Prostatic  
Hyperplasia 
N 2 18 20 
% 10 90 100 
The Control N 0 12 12 
% 0 100 100 
A B 
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Table (3): Co-localization of EBERs along with Rb gene expression in tissues with prostatic cancers. 














Positive N 11 8 19 
% 63.2 36.8 100 
Negative N 5 16 21 
% 23.8 76.2 100 
Total N 16 24 40 










Positive N 2 18 20 
% 10 90 100 
Negative N 4 14 18 
% 28.6 71.4 100 
Total N 6 14 20 










Positive N 0 0 0 
% 0 0 0 
Negative N 0 12 12 
% 0 100 100 
Total N 0 12 12 














 (Figure 2): Immunohistochemical results for Rb expression detection in prostate tumor; DAB chromogen 
stained (brown) and counter stained by Mayer's hematoxyline (blue); A. Prostate cancer with positive IHC 
reaction (100X).B. Benign prostatic hyperplasia with negative IHC reaction (10X).  
Discussion: 
Significantly high percentage of  EBERs  detection in PAC group (47.5%) was observed on comparison to BPH 
and control groups. These  results are consistent to those reported by (21) who identified EBV in 37% (7 out of 
18 cases) of prostate adenocarcinoma in US males by immunohistochemistry and PCR techniques and to those 
obtained by (22) who identified EBV in 40% (4 out of 10 cases) of malignant prostate tissue in Australia. 
However,  (23) identified EBV in 8.8% (31 out of 352 cases) in benign and malignant prostate tissues in Sweden 
while (24) identified EBV in 8% (16 out of 200 cases) of malignant prostate tissues. The small sample size 
enrolled in the studied groups has compromised the statistical power of this study to detect the effects of these 
factors under consideration. In addition, the lack of detailed clinical information attached to those prostate tissue 
samples that were included in this study has also deprived the present study to reach to a solid impression for the 
real role of those mixed viral infections in prostate carcinogenesis and in turn raised a suggestion to compel an 
integrate team-work study, at molecular and virological levels to elucidate the role of these factors and many 
other agents in prostate carcinogenesis in this country. Also in the future, it will be interesting to design 
experimental studies to understand the synergistic effect of HPV with EBV and /or HSV mixed infections in 
prostatic carcinogenesis.  
The reason for EBV to exert its oncogenic influences in a particular patients is unknown but is probably 
associated with co-factors. The findings in the research by (25)   have supported hypothesis that the prostate is a 
habitat for multiple viral and other infectious agents ,some of which have oncogenic potential. In addition ,a 
B A                                                                                               
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study has found that EBV infection may have related to the initial occurrence or further development prostate 
carcinoma. It is possible that EBV exerts its oncogenic influences in concert with co-factors including a possible 
collaboration with EBV (22). 
Among the examined tissues with Gleason's grades 6-8 ,1-5 ,and 9-10 that were collected from patients with 
prostatic cancer , 35.7% , 40.0% and 46.2% of them respectively have showed positive – in situ hybridization 
reactions for EBV-EBERs  whereas the rest of the evaluated tissues denied to show any reaction for such viral 
EBERs. It is noteworthy in this study that an increasing trend of association of EBV infection to accompany the 
deterioration in the histopathological features of the examined prostatic cancer tissues, that is an increasing 
percentages of detection of EBV EBERS with the advancing of Gleason’s grading of cancerous tissues of this 
study. This could also means, in turn, that there are an additional possible effects of EBV infection, along with 
other factors, in deterioration of the histopathology of prostatic cancerous tissues obtained from those Iraqi 
studied patients. 
Structural alterations in the entire coding regions (exons 1 to 27) of the retinoblastoma (Rb) gene in primary 
human prostate cancers were investigated, using polymerase chain reaction and single strand conformational 
polymorphism analysis of RNA. Of 25 samples obtained from patients, four (16.4%) were found to have Rb 
alterations. DNA sequencing of the PCR products revealed point mutations resulting in single amino-acid 
substitutions of exons 6 and 19 in two cases, and base deletions of exons 8 and 17 in two cases(26). Two of four 
cases with Rb mutations were moderately differentiated localized tumors and other two with Rb mutations were 
poorly differentiated tumors with metastases. Our results could suggest that RB gene mutation is involved in 
progression steps of prostate carcinogenesis. 
 EBV encodes six nuclear proteins, designated EBNA 1-6. The EBNA-5 protein of EBV is also able to bind RB 
in vitro. In addition Rb can interact with several cellular proteins, including the transcription factor E2F (19). (16) 
found a striking co-localization between the EBNA-5 (alternatively designated EBNA-LP)and Rb proteins in the 
lymphoblastoid cell line The researchers.(19) have found the COOH- terminal region of EBNA-5 is not required 
for complex formation with Rb, forms a complex with E2F during S phase. The latter complex contains cyclin A 
and cdk2 as well. The Rb has been shown to directly repress c-myc promoter activity in keratinocytes through an 
element upstream of the P1 transcription initiation site in the c-myc promoter(16).   
 
Conclusions   
The high percentage of EBV-associated PAC and BPH in our results might indicate for the oncogenic potential 
of EBV in these cases as well as pointing for  its crucial role in development, transformation and /or  progression 
of  a subset of  prostate cancers and benign prostatic hyperplasia.  
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